Expansion potential Lumos Diagnostics has been actively expanding through new contracts and fundraising, including a manufacturing agreement with Micro-Pak and a US$14m placement with plans for a further Share Purchase Plan. This indicates readiness for scaling production capabilities and broadening supplier and partner networks, presenting opportunities to cross-sell related POC test platforms, manufacturing services, and digital reader integrations to collaborators and investors.

US market focus The company has explicit US expansion activity through partnerships like MedPro for FebriDx and ongoing commercial initiatives, signaling a strong sales target in the US. Opportunities exist to pursue hospital and clinic networks, distribution agreements, and regulatory-compliant POC test offerings tailored to US healthcare providers.

Strategic partnerships Lumos is collaborating with major players such as Hologic on preterm birth assays, and with MedPro for US growth, plus manufacturing partnerships. This demonstrates a market receptiveness to joint development and co-branded testing solutions, suggesting sales plays centered on alliance-enabled product bundles and co-development engagements.

POC diagnostic focus With a portfolio that targets rapid, cost-effective point-of-care tests for infectious and inflammatory diseases and a proprietary digital reader platform, there is a clear demand for scalable, integrated POC solutions. Sales opportunities include end-to-end POC test kits, reader hardware/software licenses, and customization services for clinical settings.

Funding signals Recent fundraising activity and a published revenue range indicate growing market interest and financial momentum. This provides a favorable environment for upsell of higher-margin assay development services, ongoing consumables for existing tests, and expanded service contracts with healthcare facilities aiming to deploy additional Lumos POC solutions.